Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All antiandrogen studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchAntiandrogenAntiandrogens (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 63% Improvement Relative Risk Antiandrogens  Cheema et al.  META ANALYSIS c19early.org Favors antiandrogen Favors control

Antiandrogens for the treatment of COVID‐19 patients: A meta‐analysis of randomized controlled trials

Cheema et al., Journal of Medical Virology, doi:10.1002/jmv.28740
Apr 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
7th treatment shown to reduce risk in September 2020
 
*, now known with p = 0.000000056 from 49 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19early.org
Meta analysis of 14 antiandrogen RCTs for COVID-19, showing significantly lower mortality with treatment.
2 meta analyses show significant improvements with antiandrogens for mortality Cheema, Kotani, hospitalization Cheema, recovery Cheema, and progression Kotani.
Currently there are 49 antiandrogens for COVID-19 studies, showing 37% lower mortality [21‑50%], 47% lower ventilation [23‑64%], 36% lower ICU admission [5‑57%], 32% lower hospitalization [11‑48%], and 8% fewer cases [1‑14%].
risk of death, 63.0% lower, RR 0.37, p < 0.001.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Cheema et al., 18 Apr 2023, peer-reviewed, 9 authors.
This PaperAntiandrogensAll
{ 'DOI': '10.1002/jmv.28740', 'ISSN': ['0146-6615', '1096-9071'], 'URL': 'http://dx.doi.org/10.1002/jmv.28740', 'alternative-id': ['10.1002/jmv.28740'], 'author': [ { 'affiliation': [ { 'name': 'Department of Medicine, Division of Infectious Diseases King ' 'Edward Medical University Lahore Pakistan'}], 'family': 'Cheema', 'given': 'Huzaifa Ahmad', 'sequence': 'first'}, { 'ORCID': 'http://orcid.org/0000-0002-3795-8998', 'affiliation': [ { 'name': 'Department of Medicine, Division of Infectious Diseases King ' 'Edward Medical University Lahore Pakistan'}], 'authenticated-orcid': False, 'family': 'Rehman', 'given': 'Aqeeb Ur', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Faculty of Medicine Kafr El‐Shaikh University Kafr El‐Shaikh ' 'Egypt'}], 'family': 'Elrashedy', 'given': 'Asmaa Ahmed', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Medicine, Division of Infectious Diseases King ' 'Edward Medical University Lahore Pakistan'}], 'family': 'Mohsin', 'given': 'Aleenah', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Medicine, Division of Infectious Diseases King ' 'Edward Medical University Lahore Pakistan'}], 'family': 'Shahid', 'given': 'Abia', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0002-6021-2342', 'affiliation': [ { 'name': 'Department of Medicine, Division of Infectious Diseases King ' 'Edward Medical University Lahore Pakistan'}], 'authenticated-orcid': False, 'family': 'Ehsan', 'given': 'Muhammad', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Medicine, Division of Infectious Diseases King ' 'Edward Medical University Lahore Pakistan'}], 'family': 'Ayyan', 'given': 'Muhammad', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Internal Medicine Limerick University Hospital ' 'Limerick Ireland'}], 'family': 'Ismail', 'given': 'Heba', 'sequence': 'additional'}, { 'affiliation': [{'name': 'Galway University Hospital Galway Ireland'}], 'family': 'Almas', 'given': 'Talal', 'sequence': 'additional'}], 'container-title': 'Journal of Medical Virology', 'container-title-short': 'Journal of Medical Virology', 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': {'date-parts': [[2023, 4, 18]], 'date-time': '2023-04-18T12:41:07Z', 'timestamp': 1681821667000}, 'deposited': { 'date-parts': [[2023, 4, 18]], 'date-time': '2023-04-18T12:41:21Z', 'timestamp': 1681821681000}, 'indexed': {'date-parts': [[2023, 4, 19]], 'date-time': '2023-04-19T05:36:31Z', 'timestamp': 1681882591366}, 'is-referenced-by-count': 0, 'issue': '4', 'issued': {'date-parts': [[2023, 4]]}, 'journal-issue': {'issue': '4', 'published-print': {'date-parts': [[2023, 4]]}}, 'language': 'en', 'license': [ { 'URL': 'http://onlinelibrary.wiley.com/termsAndConditions#vor', 'content-version': 'vor', 'delay-in-days': 17, 'start': { 'date-parts': [[2023, 4, 18]], 'date-time': '2023-04-18T00:00:00Z', 'timestamp': 1681776000000}}], 'link': [ { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.28740', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '311', 'original-title': [], 'prefix': '10.1002', 'published': {'date-parts': [[2023, 4]]}, 'published-online': {'date-parts': [[2023, 4, 18]]}, 'published-print': {'date-parts': [[2023, 4]]}, 'publisher': 'Wiley', 'reference': [ {'DOI': '10.37201/req/158.2021', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_2_1'}, {'DOI': '10.1016/j.ejim.2022.05.024', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_3_1'}, {'DOI': '10.1002/jmv.28471', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_4_1'}, {'DOI': '10.1002/ptr.7724', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_5_1'}, {'DOI': '10.1002/rmv.2427', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_6_1'}, { 'DOI': '10.1016/j.jinf.2022.11.022', 'article-title': 'No evidence of clinical efficacy of famotidine for the treatment of ' 'COVID‐19 in a systematic review and meta‐analysis', 'author': 'Cheema HA', 'doi-asserted-by': 'crossref', 'first-page': '154', 'journal-title': 'J Infect', 'key': 'e_1_2_8_7_1', 'volume': '86', 'year': '2022'}, { 'DOI': '10.1016/j.jinf.2022.10.012', 'article-title': 'Efficacy and safety of fluvoxamine for the treatment of COVID‐19 ' 'patients: a systematic review and meta‐analysis', 'author': 'Cheema HA', 'doi-asserted-by': 'crossref', 'first-page': '702', 'issue': '6', 'journal-title': 'J Infect', 'key': 'e_1_2_8_8_1', 'volume': '85', 'year': '2022'}, { 'DOI': '10.1136/jclinpath-2020-206987', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_9_1'}, {'DOI': '10.1136/bmj.n71', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_10_1'}, {'DOI': '10.1136/bmj.l4898', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_11_1'}, { 'DOI': '10.1210/jendso/bvac017', 'article-title': 'A randomized trial of sitagliptin and spironolactone with combination ' 'therapy in hospitalized adults with COVID‐19', 'author': 'Abbasi F', 'doi-asserted-by': 'crossref', 'first-page': '1', 'issue': '4', 'journal-title': 'J Endocr Soc', 'key': 'e_1_2_8_12_1', 'volume': '6', 'year': '2022'}, { 'DOI': '10.1056/EVIDoa2200145', 'article-title': 'Oral sabizabulin for high‐risk, hospitalized adults with Covid‐19: ' 'interim analysis', 'author': 'Barnette KG', 'doi-asserted-by': 'crossref', 'issue': '9', 'journal-title': 'NEJM Evid', 'key': 'e_1_2_8_13_1', 'volume': '1', 'year': '2022'}, { 'DOI': '10.1016/j.eururo.2021.12.013', 'article-title': 'A phase 2 trial of the effect of antiandrogen therapy on COVID‐19 ' 'outcome: no evidence of benefit, supported by epidemiology and in vitro ' 'data', 'author': 'Welén K', 'doi-asserted-by': 'crossref', 'first-page': '285', 'issue': '3', 'journal-title': 'Eur Urol', 'key': 'e_1_2_8_14_1', 'volume': '81', 'year': '2022'}, { 'article-title': 'Finasteride in hospitalized adult males with COVID‐19: a risk factor ' 'for severity of the disease or an adjunct treatment: a randomized ' 'controlled clinical trial', 'author': 'Zarehoseinzade E', 'issue': '1', 'journal-title': 'Med J Islam Repub Iran', 'key': 'e_1_2_8_15_1', 'volume': '35', 'year': '2021'}, { 'key': 'e_1_2_8_16_1', 'unstructured': 'NCT04870606. Proxalutamide (GT0918) treatment for outpatients with mild ' 'or moderate COVID‐19 illnessClinicalTrials.gov.2022. Accessed March 8 ' '2023.https://www.prnewswire.com/news-releases/kintor-pharmas-proxalutamide-demonstrated-reduction-in-hospitalizationmortality-for-patients-with-mild-to-moderate-covid-19-in-phase-iii-mrct-study-301518525.html'}, { 'key': 'e_1_2_8_17_1', 'unstructured': 'Veru Inc. COVID‐19 Treatment of Severe Acute Respiratory Syndrome With ' 'Veru‐111.ClinicalTrials.gov.2021. Accessed March 8 ' '2023.https://clinicaltrials.gov/ct2/show/results/NCT04388826'}, { 'article-title': 'Proxalutamide (GT0918) reduces the rate of hospitalization in ' 'mild‐to‐moderate COVID‐19 female patients: a randomized double‐blinded ' 'placebo‐controlled two‐arm parallel trial', 'author': 'Adsuara Cadegiani F', 'journal-title': 'medRxiv', 'key': 'e_1_2_8_18_1', 'year': '2021'}, { 'article-title': 'Final results of a randomized, placebo‐controlled, two‐arm, parallel ' 'clinical trial of proxalutamide for hospitalized COVID‐19 patients: a ' 'multiregional, joint analysis of the proxa‐rescue AndroCoV trial', 'author': 'Cadegiani FA', 'issue': '12', 'journal-title': 'Cureus', 'key': 'e_1_2_8_19_1', 'volume': '13', 'year': '2021'}, { 'article-title': 'Early antiandrogen therapy with dutasteride reduces viral shedding, ' 'inflammatory responses, and time‐to‐remission in males with COVID‐19: a ' 'randomized, double‐blind, placebo‐controlled interventional trial ' '(EAT‐DUTA AndroCoV trial–biochemical)', 'author': 'Cadegiani FA', 'issue': '2', 'journal-title': 'Cureus', 'key': 'e_1_2_8_20_1', 'volume': '13', 'year': '2021'}, { 'article-title': '13 cis retinoic acid improved the outcomes of COVID‐19 patients. A ' 'randomized clinical trial', 'author': 'Elkazzaz M', 'journal-title': 'medRxiv', 'key': 'e_1_2_8_21_1', 'year': '2022'}, { 'article-title': 'Mineralocorticoid receptor antagonist (potassium canrenoate) does not ' 'influence outcome in the treatment of COVID‐19‐associated pneumonia and ' 'Fibrosis—a randomized placebo controlled clinical trial', 'author': 'Kotfis K', 'issue': '2', 'journal-title': 'Pharm', 'key': 'e_1_2_8_22_1', 'volume': '15', 'year': '2022'}, { 'DOI': '10.1016/j.eclinm.2022.101450', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_23_1'}, { 'DOI': '10.1001/jamanetworkopen.2022.7852', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_24_1'}, { 'article-title': 'Phase 2 randomised placebo‐controlled trial of spironolactone and ' 'dexamethasone versus dexamethasone in COVID‐19 hospitalised patients in ' 'Delhi', 'author': 'Wadhwa B', 'journal-title': 'medRxiv', 'key': 'e_1_2_8_25_1', 'year': '2022'}, {'DOI': '10.1530/ERC-20-0165', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_26_1'}, {'DOI': '10.1007/s00345-021-03810-6', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_27_1'}, { 'article-title': 'Effects of androgen deprivation therapy on COVID‐19 in patients with ' 'prostate cancer: a systematic review and meta‐analysis', 'author': 'Karimi A', 'first-page': '577', 'journal-title': 'Urol J', 'key': 'e_1_2_8_28_1', 'volume': '18', 'year': '2021'}, {'DOI': '10.1016/j.jinf.2022.03.020', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_29_1'}, {'DOI': '10.1016/j.coi.2009.05.023', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_30_1'}, {'DOI': '10.1093/cid/ciaa1022', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_31_1'}, { 'DOI': '10.1016/bs.apcsb.2019.01.001', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_32_1'}, {'DOI': '10.1093/biolre/ioy043', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_8_33_1'}], 'reference-count': 32, 'references-count': 32, 'relation': {}, 'resource': {'primary': {'URL': 'https://onlinelibrary.wiley.com/doi/10.1002/jmv.28740'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': ['Infectious Diseases', 'Virology'], 'subtitle': [], 'title': 'Antiandrogens for the treatment of COVID‐19 patients: A meta‐analysis of randomized controlled ' 'trials', 'type': 'journal-article', 'volume': '95'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit